Table 1.

Patient clinical data.

Patient		Gender		Age		BCR-ABL (%)			Breakpoint
Untreated group
1		M		61		92			b2a2
2		M		52		100			b2a2
3		M		35		100			b2a2
4		F		54		100			b2a2
5		M		46		73			b3a2
6		M		72		100			b2a2
7		F		80		100			b3a2
8		M		67		100			b3a2
9		M		59		40			b2a2
10		M		60		82			b2+b3
11		F		52		100			b3a2
12		M		37		100			b3a2
13		F		53		100			b3a2
14		M		72		100			b3a2
Patients	Gender	Age	HSCT indication	Source	DAT	BCR-ABL (%)	Breakpoint	Mutation	Follow up
Hematopoietic stem cell transplantation group
1	M	37	Disease progression	BM	224	1.60	b2a2	Absence	Relapsed
2	F	44	Failed therapy	BM	231	1,20	b3a2	Absence	Relapsed
3	F	03	Disease progression	BM	208	0.20	b3a2	_	Relapsed
4	F	63	FC	BM	1569	0.20	b3a2	Absence	Relapsed
5	M	37	Failed therapy	BM	110	0.50	b2a2	_	Relapsed
6	M	43	FC	BM	2450	0.30	b3a2	_	MMR
7	M	48	Disease progression	PBSC	80	0.75	b3a2	Absence	MMR
8	M	35	Failed therapy	BM	2352	0.03	b3a2	Absence	Relapsed
9	M	42	Failed therapy	PBSC	3561	0.01	b2a2	_	Relapsed
10	F	42	Disease progression	PBSC	3708	0.01	b3a2	_	MMR
11	F	56	FC	BM	3932	0.03	b2a2	Absence	MMR
12	M	32	FC	PBSC	3242	0.08	b2a2	_	Relapsed
13	M	21	FC	BM	1949	0.30	b3a2	Absence	Relapsed
14	M	58	Disease progression	BM	41	0.02	b2a2	_	MMR

DAT, days after transplantation; BM, bone marrow; PBSC, peripheral blood stem cell; (-), BCR-ABL mutation test was not performed; MMR, Major molecular response (BCR-ABL1 transcript level ≤ 0.1%).